The importance of non-clinical information in updating living recommendations: a case study of the Australian Living COVID-19 Clinical Guidelines.

Publication date: Jun 16, 2026

Living guidelines facilitate optimised patient care by providing up to date, evidence-based recommendations. Although a strong focus has been placed on the updating of living recommendations using clinical evidence from primary studies, the inclusion of contextualising information from non-clinical sources is equally important in maximising the applicability, appropriateness and implementability of living recommendations. We aimed to examine the range and impact of changes to the Australian Living COVID-19 Clinical Guidelines based on information from non-clinical sources. We retrospectively identified and extracted all non-clinical information updates (i. e. updates to the guideline based on information other than direct primary studies, e. g. approval or supply of therapeutics) to the COVID-19 guidelines. For each update, we recorded the location in the guideline where the change was made (e. g. recommendation, evidence-to-decision), source of change (e. g. expert consensus, consumer input, government/policy decision), and reason for change (e. g. approval/supply of therapeutics, clarity around population). Additional information was collected for specific high-impact non-clinical evidence updates. A total of 302 non-clinical changes were made to the guidelines across a three-year period. The majority of changes were made to the additional information underpinning recommendations (46%), text of the recommendation (26%) or patient preferences and values (18%), with the most prevalent source of change being expert consensus (50%). Several impactful changes were made in areas such as tocilizumab supply and in vitro evidence regarding reduced activity of monoclonal antibodies against SARS-CoV-2 Omicron subvariants. Our analysis highlights the significant quantity and diversity of information captured and incorporated within the COVID-19 clinical guidelines from non-clinical sources. Engagement with a broad range of interest holders across living guideline iterations is integral to acquiring this information and developers should consider a fourth key criterion, based on non-clinical information, to determine whether a living approach is appropriate.

Open Access PDF

Concepts Keywords
Antibodies Based
Australian Change
Patient Clinical
Tocilizumab Covid
Evidence
Guideline
Guidelines
Living
Non
Recommendations
Supply
Updates
Updating

Semantics

Type Source Name
disease MESH COVID-19
drug DRUGBANK Tocilizumab

Original Article

(Visited 2 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *